257 related articles for article (PubMed ID: 7537696)
1. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity.
Poot M; Hiller KH; Heimpel S; Hoehn H
Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle traverse in AHH-1 tk +/- human lymphoblastoid cells exposed to the chromosomal mutagen, m-amsa.
Morris SM; McGarrity LJ; Domon OE; Chen JJ; Casciano DA
Environ Mol Mutagen; 1996; 27(1):10-8. PubMed ID: 8625943
[TBL] [Abstract][Full Text] [Related]
3. Response of purified mitochondrial DNA topoisomerase I from bovine liver to camptothecin and m-AMSA.
Lin JH; Castora FJ
Arch Biochem Biophys; 1995 Dec; 324(2):293-9. PubMed ID: 8554321
[TBL] [Abstract][Full Text] [Related]
4. Carbocyclic analogues of netropsin and distamycin: DNA-binding properties and inhibition of DNA topoisomerases.
Bartulewicz D; Bielawski K; Bielawska A
Arch Pharm (Weinheim); 2002 Nov; 335(9):422-6. PubMed ID: 12447915
[TBL] [Abstract][Full Text] [Related]
5. Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity.
Habermeyer M; Fritz J; Barthelmes HU; Christensen MO; Larsen MK; Boege F; Marko D
Chem Res Toxicol; 2005 Sep; 18(9):1395-404. PubMed ID: 16167831
[TBL] [Abstract][Full Text] [Related]
6. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
7. Fluorometric assays for DNA topoisomerases and topoisomerase-targeted drugs: quantitation of catalytic activity and DNA cleavage.
Andrea JE; Adachi K; Morgan AR
Mol Pharmacol; 1991 Oct; 40(4):495-501. PubMed ID: 1656189
[TBL] [Abstract][Full Text] [Related]
8. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
Adlakha RC; Ashorn CL; Chan D; Zwelling LA
Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251
[TBL] [Abstract][Full Text] [Related]
9. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Utsugi T; Mattern MR; Mirabelli CK; Hanna N
Cancer Res; 1990 May; 50(9):2636-40. PubMed ID: 2158396
[TBL] [Abstract][Full Text] [Related]
11. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
12. Modulation of topoisomerase II catalytic activity by DNA minor groove binding agents distamycin, Hoechst 33258, and 4',6-diamidine-2-phenylindole.
Woynarowski JM; McHugh M; Sigmund RD; Beerman TA
Mol Pharmacol; 1989 Feb; 35(2):177-82. PubMed ID: 2465485
[TBL] [Abstract][Full Text] [Related]
13. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
14. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
15. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle effects of the DNA topoisomerase inhibitors camptothecin and m-AMSA in lymphoblastoid cell lines from patients with Fanconi anemia.
Poot M; Epe B; Hoehn H
Mutat Res; 1992 Nov; 270(2):185-9. PubMed ID: 1383735
[TBL] [Abstract][Full Text] [Related]
17. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
18. Effect of cell proliferation and chromatin conformation on intercalator-induced, protein-associated DNA cleavage in human brain tumor cells and human fibroblasts.
Zwelling LA; Estey E; Silberman L; Doyle S; Hittelman W
Cancer Res; 1987 Jan; 47(1):251-7. PubMed ID: 3024817
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle dependence of sister chromatid exchange induction by DNA topoisomerase II inhibitors in Chinese hamster V79 cells.
Dillehay LE; Denstman SC; Williams JR
Cancer Res; 1987 Jan; 47(1):206-9. PubMed ID: 3024815
[TBL] [Abstract][Full Text] [Related]
20. DNA binding properties of minor groove binders and their influence on the topoisomerase II cleavage reaction.
Bell A; Kittler L; Löber G; Zimmer C
J Mol Recognit; 1997; 10(6):245-55. PubMed ID: 9770648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]